Kaneh Bosm BioTechnology (CSE:KBB) announced the acquisition of portfolio company EU Cannabis which holds a license application process for medical cannabis in Greece.

As quoted in the press release:


EU Cannabis controls a 13-acre land package situated in Northern Greece, which upon receipt of the medicinal Cannabis licence will be dedicated to medical grade Cannabis cultivation, extraction, distribution, as well as research and development. In the coming days, EU Cannabis plans to commence the installation of fencing and security gates according to established best practice guidelines. While awaiting conditional approval from the Greek government, EU Cannabis will concurrently finalize an alarm, signage and security plan that is fully compliant with Greece’s current medical Cannabis regulatory environment.

Eugene Beukman, Chief Executive Officer of Kaneh Bosm states, “EU Cannabis affords Greece a turnkey service offering that will allow for the expedited development of a vertically integrated medical Cannabis facility. By leveraging access to capital, global connections and Cannabis expertise, EU Cannabis will act as a partner and advisor to the Greek government’s quest to establish a safe and sustainable medical Cannabis industry. EU Cannabis provides an unparalleled network of local partners and industry expertise necessary achieve a world-class Cannabis operation. EU Cannabis’ expanding cultivation capabilities will be complemented by Kaneh Bosm’s established distribution network of approximately 35,000 pharmacies throughout 16 countries”.

Upon receiving conditional approval from the appropriate Greek authorities, EU Cannabis plans to break ground on the construction of three separate structures with a total footprint of 97,000 square feet.

Click here to read the full press release.

Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the ongoing U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

“We would like to welcome Dr. Moody as a medical and clinical advisor to our team and we look forward to his contributions in our ongoing FDA Phase 3 clinical study as well as expanding our COVID-19 studies in Canada,” said Michael Frank, CEO of Revive. “Dr. Moody’s experience in clinical epidemiology, data analysis and research are key to our FDA Phase 3 study as we gather clinical data from patients enrolled.”

Keep reading... Show less

– FinCanna Capital Corp. (CSE:CALI) (OTCQB:FNNZF), based in Vancouver, BC today announced that Andriyko Herchak, CEO, will present live at VirtualInvestorConferences.com on December 3 rd .

Keep reading... Show less

First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support patients with posttraumatic stress disorder

Keep reading... Show less

Multi-year partnership designates BioSteel as new official sports drink of Philadelphia 76ers team, Training Complex, and the presenting partner of 76ers Training Camp

BioSteel today announced a multi-year deal with the Philadelphia 76ers, making the sports hydration company the official sports drink of the team. BioSteel will also serve as a partner of the Philadelphia 76ers Training Complex, and the presenting partner for 76ers Training Camp, which begins next week.

Keep reading... Show less

Achievements with Scalability and Compatibility Pave Way for Next Phase of Advancement

Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) is excited to announce that the Company’s holding, Arcology, a cluster-computing powered AI blockchain ecosystem with unlimited scalability, has updated its working roadmap in response to its Testnet 1.0 results

Keep reading... Show less